Hatef Mehrabian

Hatef Mehrabian

Auto-generated profile, based on publicly available information

Hatef Mehrabian

Physical Sciences, Sunnybrook Research Institute, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HMHatef Mehrabian
Hatef Mehrabian
KDKimberly L. Desmond
Kimberly L. Desmond
HSHany Soliman
Hany Soliman
ASArjun Sahgal
Arjun Sahgal
GSGreg J. Stanisz
Greg J. Stanisz
Purpose: Stereotactic radiosurgery (SRS) is a common treatment used in patients with brain metastases and is associated with high rates of local control, however, at the risk of radiation necrosis. It is difficult to differentiate radiation necrosis from tumor progression using conventional MRI, making it a major diagnostic dilemma for practitioners. This prospective study investigated whether chemical exchange saturation transfer (CEST) was able to differentiate these two conditions. Experimental Design: Sixteen patients with brain metastases who had been previously treated with SRS were included. Average time between SRS and evaluation was 12.6 months. Lesion type was determined by pathology in 9 patients and the other 7 were clinically followed. CEST imaging was performed on a 3T Philips scanner and the following CEST metrics were measured: amide proton transfer (APT), magnetization transfer (MT), magnetization transfer ratio (MTR), and area under the curve for CEST peaks corresponding to amide and nuclear Overhauser effect (NOE). Results: Five lesions were classified as progressing tumor and 11 were classified as radiation necrosis (using histopathologic confirmation and radiographic follow-up). The best separation was obtained by NOEMTR (NOEMTR,necrosis = 8.9 ± 0.9%, NOEMTR,progression = 12.6 ± 1.6%, P < 0.0001) and AmideMTR (AmideMTR,necrosis = 8.2 ± 1.0%, AmideMTR,progression = 12.0 ± 1.9%, P < 0.0001). MT (MTnecrosis = 4.7 ± 1.0%, MTprogression = 6.7 ± 1.7%, P = 0.009) and NOEAUC (NOEAUC,necrosis = 4.3 ± 2.0% Hz, NOEAUC,progression = 7.2 ± 1.9% Hz, P = 0.019) provided statistically significant separation but with higher P values. Conclusions: CEST was capable of differentiating radiation necrosis from tumor progression in brain metastases. Both NOEMTR and AmideMTR provided statistically significant separation of the two cohorts. However, APT was unable to differentiate the two groups. Clin Cancer Res; 23(14); 3667–75. ©2017 AACR.

1 July 2018 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
HMHatef Mehrabian
Hatef Mehrabian
SMSten Myrehaug
Sten Myrehaug
HSHany Soliman
Hany Soliman
ASArjun Sahgal
Arjun Sahgal
GSGreg J. Stanisz
Greg J. Stanisz

4 June 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
HMHatef Mehrabian
Hatef Mehrabian
JDJay Detsky
Jay Detsky
HSHany Soliman
Hany Soliman
ASArjun Sahgal
Arjun Sahgal
GSGreg J. Stanisz
Greg J. Stanisz
Brain metastases are the most common intracranial tumours and occur in 20-40% of all cancer patients. Lung cancer, breast cancer, and melanoma are the most frequent primary cancer to develop brain metastases. Treatment options include surgical resection, whole brain radiotherapy, stereotactic radiosurgery and systemic treatment such as targeted or immune therapy. Anatomical magnetic resonance imaging (MRI) of the tumour (in particular post-Gadolinium T1-weighted and T2-weighted FLAIR) provide information about lesion morphology and structure, and are routinely used in clinical practice for both detection and treatment response evaluation for brain metastases. Advanced MRI biomarkers that characterize the cellular, biophysical, micro-structural and metabolic features of tumours have the potential to improve the management of brain metastases from early detection and diagnosis, to evaluating treatment response. Magnetic resonance spectroscopy (MRS), chemical exchange saturation transfer (CEST), quantitative magnetization transfer (qMT), diffusion-based tissue microstructure imaging, trans-membrane water exchange mapping, and magnetic susceptibility weighted imaging (SWI) are advanced MRI techniques that will be reviewed in this article as they pertain to brain metastases.

30 September 2016 in Magnetic Resonance in Medicine
Verified
Journal Article
Closed access
PDF file
KDKimberly L. Desmond
Kimberly L. Desmond
HMHatef Mehrabian
Hatef Mehrabian
SCSofia Chavez
Sofia Chavez
ASArjun Sahgal
Arjun Sahgal
HSHany Soliman
Hany Soliman
GSGreg J. Stanisz
Greg J. Stanisz

19 November 2010 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
HMHatef Mehrabian
Hatef Mehrabian
GCGordon Campbell
Gordon Campbell
ASAbbas Samani
Abbas Samani
In breast elastography, breast tissue usually undergoes large compression resulting in significant geometric and structural changes. This implies that breast elastography is associated with tissue nonlinear behavior. In this study, an elastography technique is presented and an inverse problem formulation is proposed to reconstruct parameters characterizing tissue hyperelasticity. Such parameters can potentially be used for tumor classification. This technique can also have other important clinical applications such as measuring normal tissue hyperelastic parameters in vivo. Such parameters are essential in planning and conducting computer-aided interventional procedures. The proposed parameter reconstruction technique uses a constrained iterative inversion; it can be viewed as an inverse problem. To solve this problem, we used a nonlinear finite element model corresponding to its forward problem. In this research, we applied Veronda-Westmann, Yeoh and polynomial models to model tissue hyperelasticity. To validate the proposed technique, we conducted studies involving numerical and tissue-mimicking phantoms. The numerical phantom consisted of a hemisphere connected to a cylinder, while we constructed the tissue-mimicking phantom from polyvinyl alcohol with freeze-thaw cycles that exhibits nonlinear mechanical behavior. Both phantoms consisted of three types of soft tissues which mimic adipose, fibroglandular tissue and a tumor. The results of the simulations and experiments show feasibility of accurate reconstruction of tumor tissue hyperelastic parameters using the proposed method. In the numerical phantom, all hyperelastic parameters corresponding to the three models were reconstructed with less than 2% error. With the tissue-mimicking phantom, we were able to reconstruct the ratio of the hyperelastic parameters reasonably accurately. Compared to the uniaxial test results, the average error of the ratios of the parameters reconstructed for inclusion to the middle and external layers were 13% and 9.6%, respectively. Given that the parameter ratios of the abnormal tissues to the normal ones range from three times to more than ten times, this accuracy is sufficient for tumor classification.

6 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HMHatef Mehrabian
Hatef Mehrabian
SMSten Myrehaug
Sten Myrehaug
HSHany Soliman
Hany Soliman
ASArjun Sahgal
Arjun Sahgal
GSGreg J. Stanisz
Greg J. Stanisz
Quantitative magnetization transfer (qMT) was used as a biomarker to monitor glioblastoma (GBM) response to chemo-radiation and identify the earliest time-point qMT could differentiate progressors from non-progressors. Nineteen GBM patients were recruited and MRI-scanned before (Day0), two weeks (Day14), and four weeks (Day28) into the treatment, and one month after the end of the treatment (Day70). Comprehensive qMT data was acquired, and a two-pool MT model was fit to the data. Response was determined at 3–8 months following the end of chemo-radiation. The amount of magnetization transfer ( $${\bf{R}}{{\bf{M}}}_{{\bf{0b}}}/{{\bf{R}}}_{{\bf{a}}}$$ R M 0b / R a ) was significantly lower in GBM compared to normal appearing white matter (p < 0.001). Statistically significant difference was observed in $${\bf{R}}{{\bf{M}}}_{{\bf{0b}}}/{{\bf{R}}}_{{\bf{a}}}$$ R M 0b / R a at Day0 between non-progressors (1.06 ± 0.24) and progressors (1.64 ± 0.48), with p = 0.006. Changes in several qMT parameters between Day14 and Day0 were able to differentiate the two cohorts with $${\bf{R}}{{\bf{M}}}_{{\bf{0b}}}/{{\bf{R}}}_{{\bf{a}}}$$ R M 0b / R a providing the best separation (relative $${\bf{R}}{{\bf{M}}}_{{\bf{0b}}}/{{\bf{R}}}_{{\bf{a}},{\bf{Non}}-{\bf{progressor}}}$$ R M 0b / R a , Non − progressor = 1.34 ± 0.21, relative $${\bf{R}}{{\bf{M}}}_{{\bf{0b}}}/{{\bf{R}}}_{{\bf{a}},{\bf{progressor}}}$$ R M 0b / R a , progressor = 1.07 ± 0.08, p = 0.031). Thus, qMT characteristics of GBM are more sensitive to treatment effects compared to clinically used metrics. qMT could assess tumor aggressiveness and identify early progressors even before the treatment. Changes in qMT parameters within the first 14 days of the treatment were capable of separating early progressors from non-progressors, making qMT a promising biomarker to guide adaptive radiotherapy for GBM.